Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

Oncogenesis

Volumn 1, Issue 7, 2012, Pages

  Henjes, F ^a   Bender, C ^a   Von Der Heyde, S ^b   Braun, L ^c   Mannsperger, H A ^a   Schmidt, C ^a   Wiemann, S ^a   Hasmann, M ^d   Aulmann, S ^c   Beissbarth, T ^b   Korf, U ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

EGFR; ERBB2; erlotinib; HER2; pertuzumab; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERTUZUMAB; PROTEIN KINASE B; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

EID: 84868273967     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.16     Document Type: Article

References (49)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
2. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-5287. (Pubitemid 26315047)
3. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res 2003; 63: 1130-1137. (Pubitemid 36278448)
4. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996; 15: 254-264. (Pubitemid 26029205)
5. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269: 14661-14665.
6. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
8. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7: 153.
9. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-446. (Pubitemid 30208162)
10. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749. (Pubitemid 32691885)
11. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527. (Pubitemid 44854747)
12. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-280. (Pubitemid 34260234)
13. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-5847.
14. Junttila TT, Akita RW, Parsons K, Fields C, Lewis PGD, Friedman LS et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15: 429-440.
15. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317-328. (Pubitemid 38482068)
16. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-9336.
17. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-475.
18. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119.
19. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010; 9: 1489-1502.
20. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127. (Pubitemid 39485684)
21. Sahin O, Frohlich H, Lobke C, Korf U, Burmester S, Majety M et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol 2009; 3: 1.
22. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310. (Pubitemid 46763022)
23. Hidalgo M. Erlotinib: preclinical investigations. Oncology 2003; 17(Suppl 12): 11-16.
24. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8: 11.
25. Schneeweiss A, Kolay S, Aulmann S, Von Minckwitz G, Torode J, Koehler M et al. Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). Anticancer Drugs 2004; 15: 235-238. (Pubitemid 38429415)
26. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19: 3159-3167. (Pubitemid 30428195)
27. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005; 1: 2005 0008.
28. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137. (Pubitemid 33674041)
29. Hellyer NJ, Kim MS, Koland JG. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem 2001; 276: 42153-42161.
30. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006; 439: 168-174. (Pubitemid 43083134)
31. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167: 399-403. (Pubitemid 39489047)
32. Lane HA, Motoyama AB, Beuvink I, Hynes NE. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 2001; 12(Suppl 1): S21-S22. (Pubitemid 32750580)
33. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516. (Pubitemid 44036456)
34. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21: 177-184.
35. Loebke C, Sueltmann H, Schmidt C, Henjes F, Wiemann S, Poustka A et al. Infraredbased protein detection arrays for quantitative proteomics. Proteomics 2007; 7: 558-564. (Pubitemid 46362619)
36. Niu G, Carter WB. Human epidermal growth factor receptor 2 regulates angiopoietin-expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 2007; 67: 1487-1493. (Pubitemid 46383372)
37. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene. 29: 5193-5203.
38. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-11128. (Pubitemid 41713383)
39. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 28: 1138-1144.
40. Gianni L, Pienkowski T, Im YH, Roman L, LM T, Liu MC et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet 2011; 11: 70336-70339.
41. Hughes JB, Berger C, Rodland MS, Hasmann M, Stang E, Madshus IH. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther 2009; 8: 1885-1892.
42. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010; 16: 1509-1519.
43. Shattuck DL, Miller JK, Carraway 3rd KL, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008; 68: 1471-1477. (Pubitemid 351346855)
44. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. Jul 128: 447-456.
45. Chang S, Chen W, Yang J. Another formula for calculating the gene change rate in real-time RT-PCR. Mol Biol Rep 2009; 36: 2165-2168.
46. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2011.
47. Han J, Kamber M. Data Mining: Concepts and Techniques. 2nd edn (Morgan Kaufman: Waltham, MA, USA, 2000).
48. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucl Acid Res 2002; 30: 207-210. (Pubitemid 34679544)
49. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF et al. NCBI GEO: archive for functional genomics data sets-10 years on. Nucl Acids Res 2011; 39: D1005-D1010.